Valuation: Estimating What a Business Is Actually Worth
A stock's price tells you what someone was willing to pay for it a moment ago, not what the underlying business is actually worth, and confusing the two is how bubbles form and how genuine bargains get overlooked. Valuation is the disciplined attempt to estimate that underlying worth, and every method for doing it rests on assumptions precise enough to look scientific and uncertain enough to be wrong.
The core principle
Valuation is the process of estimating what a company, or any income-producing asset, is actually worth, as distinct from what it currently trades for. There is no single correct method; instead, analysts generally rely on three broad families of approach, and careful work usually triangulates across more than one.
The first family is relative valuation, comparing a company's price to some measure of its fundamentals, most commonly earnings (price to earnings), book value (price to book), sales (price to sales), or operating cash flow (enterprise value to EBITDA), and then comparing that ratio against peers or the company's own history. Relative valuation is fast and intuitive but entirely dependent on the comparison group actually being comparable in growth, margin, and risk profile.
The second family is intrinsic valuation, most commonly discounted cash flow (DCF) analysis, which projects a company's future free cash flows and discounts them back to today's dollars using a required rate of return that reflects the investment's risk. The core formula for a simplified, constant-growth perpetuity is:
value = cash flow × (1 + growth rate) ÷ (discount rate − growth rate)
The third family is asset-based valuation, estimating what a company's assets would be worth if sold or liquidated, most useful for asset-heavy businesses like banks, insurers, and real estate holding companies, and least useful for asset-light businesses like software firms, where most of the value lives in intangibles a balance sheet does not fully capture.
How the math works
Example 1: a discounted cash flow model and its sensitivity. A company is projected to generate $50,000,000 in free cash flow this year, growing at 5% annually in perpetuity, with investors requiring a 9% return given the company's risk profile. Using the constant-growth formula, estimated value is $50,000,000 × 1.05 ÷ (0.09 − 0.05) = $52,500,000 ÷ 0.04 = $1,312,500,000. Now change only the discount rate, from 9% to 8%, holding growth constant at 5%: value becomes $52,500,000 ÷ (0.08 − 0.05) = $52,500,000 ÷ 0.03 = $1,750,000,000. A single one percentage point change in the discount rate assumption moved the estimated value by ($1,750,000,000 − $1,312,500,000) ÷ $1,312,500,000 ≈ 33%. That is the entire case for treating any DCF output as a range, not a precise figure: the model's mathematical form is exact, but its inputs are estimates with real uncertainty attached.
Example 2: relative valuation against peers. Company A trades at $40 per share with earnings per share of $2.50, for a price to earnings ratio of $40 ÷ $2.50 = 16. The peer group of similarly sized, similarly growing competitors trades at an average P/E of 22. If Company A's growth, margins, and risk are genuinely comparable to its peers, applying the peer multiple to its own earnings suggests a fair value estimate of 22 × $2.50 = $55 per share, implying the stock may be undervalued by ($55 − $40) ÷ $40 = 37.5% relative to its peer group. That conclusion depends entirely on the comparability assumption holding up; if Company A actually deserves a discount to peers because of weaker margins or more debt, the 37.5% "discount" may simply be the market pricing in a real difference, not a mispricing to exploit.
How it shows up in real portfolios
Individual investors most often encounter valuation through simple screens, filtering for stocks with a low P/E or price to book ratio relative to the broader market. This can be a legitimate starting point, but it is only a starting point: a stock can trade at a low multiple because it is genuinely undervalued, or because the market has correctly priced in deteriorating fundamentals that the ratio alone does not reveal, a pattern experienced investors call a value trap.
Analysts valuing early-stage or pre-revenue companies, common in biotechnology and speculative technology names, lean almost entirely on intrinsic valuation, since there are few or no current earnings to anchor a relative multiple. In these cases, the majority of a DCF's estimated value often sits in the terminal value, the cash flows projected many years or decades into the future, which means the valuation is extraordinarily sensitive to long-horizon assumptions that no one can verify with any real confidence today.
Bond and fixed-income valuation works on a different, more mechanical basis than equity valuation, since a bond's future cash flows are contractually specified rather than estimated. Discounting a bond's known coupon payments and principal repayment at the current market yield produces a precise price with very little of the assumption-driven uncertainty that plagues equity DCF models, which is one reason bond pricing is generally treated as closer to arithmetic than to judgment, while equity valuation remains, at its core, a disciplined exercise in estimating an unknowable future.
A useful high-earning-professional scenario: a physician considering buying into a private medical practice partnership is typically presented with a purchase price expressed as a multiple of the practice's EBITDA, say 6 times. Before agreeing, the physician benefits from sanity-checking that multiple against comparable public healthcare company valuations, and from asking what specific one-time addbacks or adjustments inflated the reported EBITDA figure, since a purchase price built on an inflated earnings base is a valuation error dressed up as a simple, defensible multiple.
Behavioral factors distort valuation judgment as reliably as any mathematical error does. Anchoring on a stock's own 52-week high or on the price an investor originally paid, rather than valuing the business fresh against its current fundamentals, is one of the most common and most costly mistakes even experienced investors make, since neither number has any actual bearing on what the business is worth today. A disciplined valuation process treats every holding, new or long-owned, as though it were being evaluated for the first time, with today's facts and today's price, not the facts and price of whenever it was originally purchased.
Actionable breakdown
- Use more than one method:
- Relative valuation for a quick sanity check against peers.
- Intrinsic valuation for a deeper, assumption-driven estimate.
- Asset-based valuation as a floor for asset-heavy businesses.
- Stress-test every model:
- Vary the growth rate and discount rate independently.
- Note how far the answer swings on small assumption changes.
- Question a "cheap" multiple before trusting it:
- Compare only genuinely similar businesses.
- Ask why the market is pricing it where it is.
Private company valuation adds yet another layer of difficulty, since there is no public market price to sanity-check an estimate against at all. Business appraisers valuing a private medical or legal practice, for instance, must rely almost entirely on comparable private transactions and industry-standard multiples, which trade with far less transparency and far less frequency than public market data, making a private valuation inherently a wider-range estimate than a comparable public company valuation would be.
Common pitfalls
- Treating a DCF or multiple-based output as an exact, guaranteed figure rather than an estimate built on assumptions that can each be reasonably challenged.
- Comparing valuation ratios across genuinely different industries, where "normal" multiples differ structurally and a bank's P/E has little bearing on a software company's.
- Chasing a low multiple as a buy signal without asking whether the market has already, correctly, priced in a real deterioration in the business.
- Anchoring to what you originally paid for a stock instead of valuing it fresh against today's facts and today's price.
Related concepts
For the intrinsic method behind Example 1, see DCF and free cash flow. For the relative ratios behind Example 2, see P/E ratio, price to book, and EBITDA. For the investing philosophy built most directly on this concept, see value investing. For a fuller framework, see the guides on valuation ratios and stock analysis.
The bottom line
Valuation gives you a disciplined, defensible estimate of worth, never a fact, so hold every number it produces as a range built on assumptions you should be able to defend individually.